References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., &
Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries.CA: a cancer journal for clinicians, 68 (6), 394-424.
Gao, X., Wen, X., He, H., Zheng, L., Yang, Y., Yang, J., . . . Zhang, S.
(2020). Knockdown of CDCA8 inhibits the proliferation and enhances the
apoptosis of bladder cancer cells. PeerJ, 8 , e9078.
doi:10.7717/peerj.9078
Garg, M. (2016). Epithelial plasticity in urothelial carcinoma: Current
advancements and future challenges. World J Stem Cells, 8 (8),
260-267. doi:10.4252/wjsc.v8.i8.260
Kobayashi, T. (2016). Understanding the biology of urothelial cancer
metastasis. Asian J Urol, 3 (4), 211-222.
doi:10.1016/j.ajur.2016.09.005
Leal, J., Luengo-Fernandez, R., Sullivan, R., & Witjes, J. A. (2016).
Economic Burden of Bladder Cancer Across the European Union. Eur
Urol, 69 (3), 438-447. doi:10.1016/j.eururo.2015.10.024
Li, X., Xu, M., Ding, L., & Tang, J. (2019). MiR-27a: A Novel Biomarker
and Potential Therapeutic Target in Tumors. J Cancer, 10 (12),
2836-2848. doi:10.7150/jca.31361
Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., Padala, S. A., &
Barsouk, A. (2020). Epidemiology of Bladder Cancer. Med Sci
(Basel), 8 (1). doi:10.3390/medsci8010015
Soria, F., Droller, M. J., Lotan, Y., Gontero, P., D’Andrea, D., Gust,
K. M., . . . Shariat, S. F. (2018). An up-to-date catalog of available
urinary biomarkers for the surveillance of non-muscle invasive bladder
cancer. World J Urol, 36 (12), 1981-1995.
doi:10.1007/s00345-018-2380-x